Scinai Immunotherapeutics Ltd. - American Depositary Shares (SCNI)
1.5600
-0.0500 (-3.11%)
NASDAQ · Last Trade: Sep 4th, 5:18 PM EDT
Detailed Quote
| Previous Close | 1.610 |
|---|---|
| Open | 1.560 |
| Bid | 1.520 |
| Ask | 1.600 |
| Day's Range | 1.520 - 1.608 |
| 52 Week Range | 1.400 - 6.180 |
| Volume | 58,315 |
| Market Cap | 719.61M |
| PE Ratio (TTM) | 1,560.00 |
| EPS (TTM) | 0.0 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 310,649 |
Chart
About Scinai Immunotherapeutics Ltd. - American Depositary Shares (SCNI)
Scinai Immunotherapeutics Ltd is a biotechnology company focused on the development of innovative therapeutic solutions aimed at treating various types of cancers and autoimmune diseases. The company leverages advanced immunotherapy techniques to harness the body’s immune system, enhancing its ability to identify and combat disease. By conducting research and clinical trials, Scinai seeks to bring novel treatments to market that can improve patient outcomes and offer hope for conditions that currently have limited treatment options. Their commitment to scientific advancement in the field of immunotherapy positions them as a key player in the evolving landscape of medical therapeutics. Read More
News & Press Releases
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports First-Half 2025 Results and Strengthened Cash Position
Scinai Immunotherapeutics (NASDAQ: SCNI) reported revenues of $773,000 for the six months ended June 30, 2025, up from $284,000 in the prior-year period, reflecting continued growth in its CDMO business. R&D expenses fell to $1.24 million from $2.79 million, while marketing, general and administrative expenses rose to $1.26 million from $1.00 million. Net loss narrowed to $4.13 million compared to $4.48 million a year earlier. Cash and equivalents totaled $989,000 as of June 30, with an additional $4.2 million raised in July and August under the Company’s Standby Equity Purchase Agreement, significantly strengthening liquidity. Scinai advanced its anti-IL-17 NanoAb program, filed new patents under its Max Planck collaboration, and is pursuing up to €27 million in grant funding to support clinical trials and pipeline development, while its CDMO unit booked $1.0 million in 2025 service orders through August.
Via Investor Brand Network · September 2, 2025
Via Benzinga · August 21, 2025
Via Benzinga · August 20, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · August 13, 2025
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.
Via Chartmill · July 29, 2025
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Publishes Peer-Reviewed Data Supporting PC111 as Potential Disease Modifier
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company developing inflammation and immunology biological products and providing boutique CDMO services, announced the publication of a peer-reviewed article in the Journal of Dermatological Treatment confirming the disease-modifying potential of PC111, a first-in-class human anti-Fas Ligand monoclonal antibody. The study demonstrated PC111’s ability to prevent blister formation in humanized models of pemphigus by targeting soluble Fas Ligand, offering a differentiated, non-immunosuppressive approach. Data also highlighted potential use in SJS/TEN, a life-threatening dermatological condition. CEO Amir Reichman said the findings reinforce PC111’s potential to transform treatment for these high unmet-need indications and deliver meaningful value to patients and shareholders.
Via Investor Brand Network · July 29, 2025
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · July 29, 2025
Via Benzinga · July 29, 2025
Via Benzinga · July 29, 2025
Via Benzinga · July 2, 2025
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Highlights PC111 Breakthrough After Scientist Wins Top Italian Dermatology Award
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharma company focused on inflammation and immunology, announced that Dr. Roberta Lotti of Pincell Srl has won the “Oscar of Italian Dermatology” from SIDeMaST for her research on PC111, a first-in-class anti-Fas Ligand monoclonal antibody. The study, published under the title “Blocking soluble Fas Ligand ameliorates pemphigus” , confirms PC111’s ability to block blister formation by preventing keratinocyte apoptosis in pemphigus vulgaris. Scinai holds an option to acquire Pincell and is advancing PC111 as a lead asset, emphasizing its potential as a non-immunosuppressive, disease-modifying treatment for severe autoimmune skin conditions.
Via Investor Brand Network · June 26, 2025
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Highlights Growth and SEPA Funding Ahead of BIO 2025 CEO Participation
Scinai Immunotherapeutics (NASDAQ: SCNI) announced that CEO Amir Reichman will participate in the BIO International Convention 2025, taking place June 16–19 in Boston. The company will present recent strategic, operational, and financial milestones, including its rapid CDMO business growth and progress on its nanobody pipeline. Scinai recently secured $1.38 million in funding via its Standby Equity Purchase Agreement with Yorkville Advisors, boosting capital without warrants or additional dilution. The company reaffirmed 2025 CDMO revenue guidance of $2 million and targets breakeven in 2026.
Via Investor Brand Network · June 12, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Via Chartmill · June 6, 2025
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Via Chartmill · June 6, 2025
Via Benzinga · June 5, 2025
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.
Via Chartmill · June 5, 2025
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Italian Clearance for Option to Acquire Biotech Firm Pincell
Scinai Immunotherapeutics (NASDAQ: SCNI) announced it has received regulatory clearance under Italy’s Golden Power regulation to proceed with its option to acquire 100% of Pincell S.r.l., an Italian biotech company. The approval, issued by Italy’s Coordination Group and Ministry of Health, supports Scinai’s strategic move to expand its inflammation and immunology pipeline. Pincell’s lead asset, PC111—a monoclonal antibody targeting the Fas/FasL pathway—holds Orphan Drug Designation in Pemphigus and is being developed for severe skin disorders. The acquisition remains subject to final conditions, including a €12 million grant decision expected later this summer.
Via Investor Brand Network · June 5, 2025
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q1 Revenue Growth Driven by CDMO Contracts, Net Loss Narrows
Scinai Immunotherapeutics (NASDAQ: SCNI) reported first quarter 2025 financial results, posting $586K in revenue, up from zero in the prior-year period, reflecting continued expansion of its CDMO business. R&D expenses declined to $1.3M from $1.6M, while marketing, general and administrative costs held steady at $500K. The company recorded a $1.6M net loss, improving from a $2.2M loss in Q1 2024, aided by reduced R&D and financial expenses. Cash and equivalents totaled $1M at quarter-end, down from $2M a year earlier.
Via Investor Brand Network · May 30, 2025
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports $4.8 Million Net Gain in 2024, Driven by Loan-to-Equity Conversion
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharma company focused on inflammation and immunology treatments and CDMO services, reported a $4.8 million net gain for 2024, reversing a $6.5 million loss in 2023. The improvement was largely due to $14.8 million in financial income from a loan-to-equity conversion. The company posted $658,000 in revenue—its first ever—from its CDMO unit. R&D expenses remained steady at $5.6 million, while G&A costs dropped to $2.6 million. Cash and equivalents totaled $1.9 million at year-end.
Via Investor Brand Network · May 8, 2025
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Host Webinar on PC111 Antibody for Rare Skin Disorders
Scinai Immunotherapeutics (NASDAQ: SCNI) will host a webinar May 7 at 11:30 a.m. EST to discuss the treatment potential of Pincell’s novel monoclonal antibody, PC111, for rare skin conditions Pemphigus Vulgaris and SJS/TEN. The session will cover unmet medical needs, PC111’s mechanism targeting soluble Fas ligand, and development plans. The event follows Scinai’s March agreement to acquire Pincell and a related €12 million grant application under Poland’s FENG program. Panelists include executives from Scinai and Pincell, with a live Q&A segment.
Via Investor Brand Network · May 1, 2025
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell
Scinai Immunotherapeutics (NASDAQ: SCNI), announced it has signed a binding option agreement to acquire Pincell srl, an Italian biotech developing PC111, a first-in-class antibody targeting severe skin blistering disorders. In tandem, Scinai’s Polish subsidiary submitted a €12 million non-dilutive grant application under the EU’s FENG program to fund the next development phase of PC111. The agreement positions Scinai to advance treatments for high-mortality conditions like pemphigus and Stevens-Johnson Syndrome without immunosuppression, with Pincell’s leadership expected to integrate into Scinai’s expanding European operations.
Via Investor Brand Network · March 27, 2025
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Present at BIO-Europe Spring 2025
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and contract development and manufacturing (CDMO) services, announced its participation in the BIO-Europe Spring 2025 conference from March 17-19 in Milan, Italy. The company’s leadership will meet with potential pharmaceutical partners, prospective CDMO clients, and institutional investors to showcase its innovative NanoAb pipeline and biologics manufacturing capabilities. Scinai will also exhibit its CDMO services at booth #22.
Via Investor Brand Network · March 17, 2025
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters $10 Million Standby Equity Purchase Agreement
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on inflammation and immunology biological products and contract development and manufacturing organization (CDMO) services, has entered into a standby equity purchase agreement with YA II PN, Ltd., a fund managed by Yorkville Advisors Global. The agreement allows Scinai to sell up to $10 million of its American Depository Shares to Yorkville over a three-year period, subject to certain conditions, including a 9.99% beneficial ownership cap. The company retains full control over the timing and amount of any sales, with no obligations or penalties for non-use. Proceeds will support the development of Scinai’s NanoAbs programs, expansion of its CDMO business, and general corporate purposes.
Via Investor Brand Network · March 5, 2025